Janux Therapeutics Inc. (JANX) NASDAQ
$48.88 0.19 (0.39%)
Market Cap: $2.52B
As of 04/22/24 04:00 PM EDT. Market closed.
Janux Therapeutics Inc. (JANX)
NASDAQ
$48.88
0.19 (0.39%)
Market Cap: $2.52B
As of 04/22/24 04:00 PM EDT. Market closed.
janux therapeutics is an innovative biopharmaceutical company developing next-generation therapeutics based on its proprietary tumor activated t cell engager (tractr) platform technology to better treat patients suffering from cancer. janux’s initial focus is on developing a novel class of t cell engagers (tces), and its lead product candidates are designed to target clinically validated drug ... read more
Owner | Relationship | Date | Transaction | Cost | # Shares | Value($) | Total Shares | Form 4 |
Reardon Tighe | Acting Chief Financial Officer | Nov 13, 2023 | Buy | $5.87 | 849,854 | 4,988,643 | 849,854 | Nov 15, 2023, 04:48 PM |
Lichter Jay | Director | Nov 13, 2023 | Buy | $5.87 | 849,854 | 4,988,643 | 849,854 | Nov 15, 2023, 04:46 PM |
Avalon Ventures XI, L.P. | 10% Owner | Nov 13, 2023 | Buy | $5.87 | 849,854 | 4,988,643 | 849,854 | Nov 13, 2023, 07:11 PM |
RA CAPITAL MANAGEMENT, L.P. | Director | Jul 19, 2023 | Buy | $12.46 | 495,008 | 6,167,800 | 8,117,246 | Jul 21, 2023, 04:31 PM |
ORBIMED ADVISORS LLC | Director | Dec 29, 2021 | Sale | $20.30 | 40,400 | 820,120 | 2,258,566 | Dec 30, 2021, 09:00 PM |
Thompson Peter A. | Director | Dec 29, 2021 | Sale | $20.30 | 40,400 | 820,120 | 2,258,566 | Dec 30, 2021, 08:55 PM |
ORBIMED ADVISORS LLC | Director | Dec 21, 2021 | Sale | $19.00 | 119,400 | 2,268,600 | 2,295,266 | Dec 23, 2021, 04:13 PM |
Thompson Peter A. | Director | Dec 21, 2021 | Sale | $19.00 | 119,400 | 2,268,600 | 2,295,266 | Dec 23, 2021, 04:08 PM |
Thompson Peter A. | Director | Dec 16, 2021 | Sale | $19.07 | 393,300 | 7,500,231 | 2,403,566 | Dec 17, 2021, 05:16 PM |
ORBIMED ADVISORS LLC | Director | Dec 16, 2021 | Sale | $19.07 | 393,300 | 7,500,231 | 2,403,566 | Dec 17, 2021, 05:13 PM |
Thompson Peter A. | Director | Jun 15, 2021 | Buy | $17.00 | 705,853 | 11,999,501 | 2,760,366 | Jun 16, 2021, 06:20 PM |
Reardon Tighe | Acting Chief Financial Officer | Jun 15, 2021 | Buy | $17.00 | 629,411 | 10,699,987 | 4,479,492 | Jun 16, 2021, 06:11 PM |
Owner | Relationship | Date | Value($) |
Reardon Tighe | Acting Chief Financial Officer | 11/13/2023 | 4,988,643 |
Lichter Jay | Director | 11/13/2023 | 4,988,643 |
Avalon Ventures XI, L.P. | 10% Owner | 11/13/2023 | 4,988,643 |
RA CAPITAL MANAGEMENT, L.P. | Director | 07/19/2023 | 6,167,800 |
ORBIMED ADVISORS LLC | Director | 12/29/2021 | 820,120 |
Thompson Peter A. | Director | 12/29/2021 | 820,120 |
ORBIMED ADVISORS LLC | Director | 12/21/2021 | 2,268,600 |
Thompson Peter A. | Director | 12/21/2021 | 2,268,600 |
Thompson Peter A. | Director | 12/16/2021 | 7,500,231 |
ORBIMED ADVISORS LLC | Director | 12/16/2021 | 7,500,231 |
Thompson Peter A. | Director | 06/15/2021 | 11,999,501 |
Reardon Tighe | Acting Chief Financial Officer | 06/15/2021 | 10,699,987 |
Fund | # Shares Owned | % of Portfolio | % Change | Investing Style |
---|---|---|---|---|
RA CAPITAL MANAGEMENT, L.P. | 10,593,395 | 7.07% | 15.58% | Other |
ORBIMED ADVISORS LLC | 3,317,927 | 0.71% | No change | Other |
BLACKROCK INC. | 1,762,101 | 0.00048% | 7.47% | Other |
ADAGE CAPITAL PARTNERS GP, L.L.C. | 1,355,475 | 0.03% | 17.87% | Other |
GEODE CAPITAL MANAGEMENT, LLC | 408,190 | 0.00046% | 5.53% | Other |
Period of Report: 12/31/2023
10-K/10-Q Filings: View